Souhaitez-vous accéder aux communiqués récents ?

VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)( FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through...

Phase 2 findings presented at ASCO 2026 showed strong median overall survival of 19.3 months in evaluable patients, led by 29.3 months in MGMT unmethylated GBM patientsBPM31510 generally well...

NeOnc Technologies Holdings (NASDAQ: NTHI) continues to build momentum as a neuro-oncology sector trailblazer

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Early Interim Results Showed 100% Local Disease Control

EnGeneIC Honored with 2026 Breakthrough in glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York

NeOnc (NASDAQ:NTHI) is developing therapies and delivery technologies targeting aggressive brain cancers and CNS-related conditions, and could be part of t

Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. $NTHI, $ORKA, $ABVX, $SYRE

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide is proud to award...

TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), the country’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide, is proud to...

Wall St analysts are rating NeOnc Technologies (NASDAQ:NTHI) a “Buy”, as institutional investors and company insiders are buying